Champions Oncology (CSBR) Enterprise Value (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Enterprise Value of -$7.0 million in Q1 2026, up 17.15% quarter-over-quarter from -$8.5 million in Q4 2025, and down 118.77% on a YoY basis from $37.3 million in Q1 2025.
Champions Oncology (CSBR) Enterprise Value (2010 - 2026) Analysis & Trends
Champions Oncology's Enterprise Value history runs 17 years deep, the most recent figure standing at -$7.0 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 118.77% year-over-year to -$7.0 million; the TTM figure through Jan 2026 stood at -$7.0 million (down 118.77% YoY), while the FY2025 annual figure was -$9.8 million, down 273.76% from the prior year.
- Enterprise Value was -$7.0 million for Q1 2026 at Champions Oncology, up from -$8.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.6 million in Q2 2024 to a low of -$10.8 million in Q4 2022.
- Historically, Enterprise Value has averaged -$6.3 million across 5 years, with a median of -$5.5 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 50.05% in 2024, then tumbled 273.76% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$10.8 million in 2022, then jumped by 49.08% to -$5.5 million in 2023, then jumped by 50.05% to -$2.8 million in 2024, then sank by 207.01% to -$8.5 million in 2025, then gained by 17.15% to -$7.0 million in 2026.
- The last three Enterprise Value figures came in at -$7.0 million (Q1 2026), -$8.5 million (Q4 2025), and -$10.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -584.73 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -7.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -7.01 Mn |
| Oct 31, 2025 | -8.46 Mn |
| Jul 31, 2025 | -10.27 Mn |
| Apr 30, 2025 | -9.79 Mn |
| Jan 31, 2025 | -3.20 Mn |
| Oct 31, 2024 | -2.75 Mn |
| Jul 31, 2024 | -2.89 Mn |
| Apr 30, 2024 | -2.62 Mn |
| Jan 31, 2024 | -4.50 Mn |
| Oct 31, 2023 | -5.51 Mn |
| Jul 31, 2023 | -4.90 Mn |
| Oct 31, 2022 | -10.83 Mn |
| Jan 31, 2022 | -8.70 Mn |
| Jul 31, 2021 | -4.00 Mn |
| Jul 31, 2020 | -6.94 Mn |
| Apr 30, 2020 | -8.34 Mn |
| Jan 31, 2020 | -3.28 Mn |
| Oct 31, 2019 | -2.78 Mn |
| Jul 31, 2019 | -2.20 Mn |
| Apr 30, 2019 | -3.24 Mn |